Unbiased Analysis of Today's Healthcare Issues
Professor Rick Dakan (Ringling College of Art and Design) and Professor Joseph Feller (University College Cork) developed the 4D Framework for AI Fluency. What is it? Delegation: Deciding on what work should be done by humans, what work should be done by AI, and how to distribute tasks between them. Includes understanding your goals, AI capabilities,…
That is the title of my latest column in The Evidence Base. In this latest edition of Perspectives from the Healthcare Economist, Jason Shafrin (FTI Consulting and Mann School of Pharmacy, University of Southern California) examines how AI is beginning to reshape health economics and outcomes research (HEOR), from evidence generation and literature reviews to data analysis…
The Peterson Health Technology Institute (PHTI) recently released a report titled: “Administrative AI: Current Use and Potential Impact.” The report was based on a workshop PHTI convened with senior leaders from health systems, health plans, technology developers, investment firms, and federal agencies in order to discuss how technology and policy can enable AI to reduce…
From Lex Fridman’s interview with Jensen Huang, CEO of NVIDIA: …the first job that computer scientists said, AI researchers said was gonna go away was radiology because computer vision was going to achieve superhuman levels…and it did. Computer vision was superhuman in 2019….maybe a little bit later, 2020. And so it’s been a long time…
Here they are: Human-centric by design. The development and use of AI technologies align with ethical and human-centric values. Risk-based approach. The development and use of AI technologies follow a risk-based approach with proportionate validation, risk mitigation, and oversight based on the context of use and determined model risk. Adherence to standards. AI technologies adhere…
The Economist reports that many life science companies are betting big on AI to help with drug development. Why? If AI can increase their likelihood new molecules become successful drugs, the cost of drug development will fall. AI-designed molecules show an 80-90% success rate in early-stage safety trials, compared with a historical average of just…
Joe Paduda of Managed Care Matters discusses rising Workers Comp cost in California: Of particular interest is the growing prevalence of unlisted codes in physical medicine (PM). Last year saw a huge jump in PM services coded as 97799 – “unlisted physical medicine”. Note that jump happened while the use of normal/traditional/common PM codes for…
Today’s AI is not truly agentic because it’s not truly independent of you. The current crop of agents can’t set complex goals, or properly verify outputs. You have to spend a lot of effort on prompting, verifying, and system integrating. That just means the smarter you are, the smarter the AI is. It’s really amplified…
Health economics and outcomes research has already started to use AI tools such as large language models (LLM) across a diverse set of study types, including systematic literature reviews (SLR), health economic modelling (HEM) and real-world evidence (RWE). In SLRs, LLMs can assist with abstract and full-text screening, bias assessment, data extraction, and automating meta-analysis…
The answer to this question depends, not only on how well AI tools work, but also on how AI technologies are regulated by the FDA. Scott Gottlieb has some thoughts on preferred regulatory approaches in his recent article in JAMA Health Forum. Artificial intelligence tools with advanced analytical capabilities used in clinical practice, especially tools…